Free Trial
→ Watch This Robotics Demo Before March 17th (From Brownstone Research) (Ad)

Adial Pharmaceuticals 8/13/2024 Earnings Report

Adial Pharmaceuticals logo
$0.79 +0.02 (+2.21%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

Adial Pharmaceuticals EPS Results

Actual EPS
-$0.59
Consensus EPS
-$0.39
Beat/Miss
Missed by -$0.20
One Year Ago EPS
N/A

Adial Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adial Pharmaceuticals Announcement Details

Quarter
Date
8/13/2024
Time
After Market Closes

Conference Call Resources

Adial Pharmaceuticals Earnings Headlines

Adial awarded patent covering genetic approach to alcoholism by USPTO
February 19 at 9:43 AM | markets.businessinsider.com
Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies
February 19 at 9:00 AM | globenewswire.com
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
February 22, 2025 | Investors Alley (Ad)
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Significant Growth in Short Interest
February 13, 2025 | americanbankingnews.com
Adial Pharmaceuticals awarded new U.S. patent on genotype-specific treatment
February 12, 2025 | markets.businessinsider.com
EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
February 12, 2025 | finance.yahoo.com
See More Adial Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adial Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adial Pharmaceuticals and other key companies, straight to your email.

About Adial Pharmaceuticals

Adial Pharmaceuticals (NASDAQ:ADIL), a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

View Adial Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles